作者:Kerry Ten Kate、Sarah A. Laird
DOI:10.1111/1468-2346.00132
日期:2000.4
The Convention on Biological Diversity incorporates an exchange that has been described as a ‘grand bargain’ which balances the needs of both technologically and biologically endowed countries. The role of genetic resources in R&D and sales varies by industry sector, however, so it is difficult to generalize on company demand for genetic resources and fair and equitable benefit-sharing. It is important, therefore, to examine the particular features of industry R&D programmes, providers of genetic resources, and trends in benefit-sharing partnerships in specific industry sectors. This article examines markets for genetic resources, costs and duration of R&D, types of genetic resources accessed, providers of genetic resources and benefit-sharing partnerships in the pharmaceutical, biotechnology, crop protection, seed, botanical medicine, horticulture, and personal care and cosmetic industries. The article concludes that experience and ‘best practice’ in benefit-sharing have progressed quite significantly on a number of fronts in the past decade, including the development of corporate policies in response to the CBD. The most effective form of benefit-sharing, and realization of the ‘ grand bargain’ envisaged by the CBD, is found through partnerships between private-sector and source-country institutions that link commercial use with sustainable development and biodiversity conservation.
《生物多样性公约》包含了一种被描述为“重大交易”的交换,旨在平衡技术和生物资源丰富国家的需求。然而,基因资源在研发和销售中的作用因行业部门而异,因此很难对公司对基因资源的需求以及公平和公平的利益分享进行普遍化。因此,重要的是要考察特定行业研发项目的特点、基因资源的提供者以及特定行业部门利益分享伙伴关系的趋势。本文研究了制药、生物技术、作物保护、种子、草药医学、园艺以及个人护理和化妆品行业的基因资源市场、研发成本和时长、获取的基因资源类型、基因资源提供者以及利益分享伙伴关系。文章最后得出结论,过去十年中,在多个方面,利益分享的经验和“最佳实践”取得了显著进展,包括企业政策的发展,以回应生物多样性公约。实现生物多样性公约设想的“重大交易”的最有效形式是私营部门与来源国机构之间的伙伴关系,这种伙伴关系将商业使用与可持续发展和生物多样性保护联系起来。